Physician profile
Carmen Calfa
NPI 1114138534
$1,229.20
in general payments reported to CMS, 2019-2025
15 companies · $407 in 2025
The $407 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77.23 · 2020: $52.73 · 2021: $256 · 2022: $43.84 · 2023: $184 · 2024: $209 · 2025: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704 · Education: $95.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.46 |
| Education | $95.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $206.61 | 2021-2025 | |
| Daiichi Sankyo INC. | $162.26 | 2020-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $133.74 | 2019-2025 | Lynparza, Keytruda |
| Novartis Pharmaceuticals Corporation | $126.57 | 2019-2025 | |
| Mentor Worldwide LLC | $115.38 | 2021 | |
| Pfizer INC. | $98.47 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $94.22 | 2023-2025 | Enhertu |
| Stemline Therapeutics INC. | $76.41 | 2023 | Orserdu |
| Janssen Scientific Affairs, LLC | $42.62 | 2025 | Talvey, Tecvayli, Darzalex |
| Caris Mpi, INC. | $41.32 | 2025 | Mi Cancer Seek |
| Gilead Sciences, INC. | $35.76 | 2021-2023 | |
| Tersera Therapeutics LLC | $31.47 | 2024 | Zoladex |
| Veracyte, INC. | $30.58 | 2020 | |
| Amgen INC. | $18.26 | 2019 | |
| Lilly USA, LLC | $15.53 | 2023 | Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carmen Calfa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.